ADAP Advocacy has released a new infographic focused on the 340B Drug Pricing Program, reinforcing the central message of its earlier policy paper and commercial released under the same title: "340B PROGRAM: The Glue That Should Hold Our Healthcare System Together." The announcement, made as part of ADAP Advocacy's ongoing 340B Project, draws attention to what the organization describes as a growing disconnect between the program's expansion and its intended outcomes for vulnerable patients.
Congress created the 340B Drug Pricing Program to extend federal resources and improve patient care. The Affordable Care Act later added requirements for hospitals to provide free care and financial aid to poor patients, also known as charity care. However, the new infographic highlights that charity care continues to decline year after year. Meanwhile, 340B drug purchases rose above $100 billion in 2025 across more than 42,000 covered entities and over 32,000 pharmacies. This unfettered growth, according to ADAP Advocacy, is failing to deliver on the program's promise.
The infographic connects these dots, illustrating how the program's expansion has not translated into proportional benefits for patients. It continues ADAP Advocacy's '340B Too Big To Fail' national advocacy campaign, which spotlights hospitals' declining charity care, rising healthcare executive compensation, and exploding patient medical debt, among other issues. The infographic is available for download online at https://tinyurl.com/y6asjaw2.
For readers, this news matters because the 340B program is a critical component of the U.S. healthcare safety net, designed to help providers stretch scarce federal resources to better serve low-income and uninsured patients. If charity care is declining even as the program grows, it suggests that the benefits may be accruing to hospitals and other entities rather than to the patients the program was meant to help. This could have significant implications for patients living with HIV/AIDS, who rely on programs like the AIDS Drug Assistance Programs (ADAPs) that ADAP Advocacy supports. ADAP Advocacy's mission is to promote and enhance ADAPs and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.
As the 340B program continues to expand, the debate over its effectiveness and accountability is likely to intensify. ADAP Advocacy's new infographic adds to the growing body of scrutiny, providing a visual tool for advocates and policymakers. The implications extend beyond HIV/AIDS care, touching on broader questions about healthcare spending, hospital transparency, and the sustainability of safety-net programs. With 340B purchases exceeding $100 billion, the program's scale makes it a pivotal issue in national healthcare discussions. Stakeholders across the spectrum will need to consider whether the program is truly serving as the glue that holds the healthcare system together or if it is inadvertently contributing to the very disparities it was designed to address.
